Free Access
Dement Geriatr Cogn Disord 2007;24:185–192
(DOI:10.1159/000105927)

Metabolic Syndrome and Dementia Risk in a Multiethnic Elderly Cohort

Muller M.a, i · Tang M.-X.a, b · Schupf N.c-e, h · Manly J.J.a, c, f · Mayeux R.a, c-f · Luchsinger J.A.a, c, d, g
aGertrude H. Sergievsky Center, bDivision of Biostatistics, Joseph P. Mailman School of Public Health, cTaub Institute for Research of Alzheimer’s Disease and the Aging Brain, and dDepartment of Epidemiology, Joseph P. Mailman School of Public Health, Columbia University, eDepartment of Psychiatry, fDepartment of Neurology, and gDivision of General Medicine, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, N.Y., and hLaboratory of Epidemiology, NYS Institute for Basic Research in Developmental Disabilities, Staten Island, N.Y., USA; iDepartment of Geriatric Medicine, University Medical Center, Utrecht, The Netherlands
email Corresponding Author


 goto top of outline Key Words

  • Metabolic syndrome
  • Alzheimer’s disease
  • Diabetes
  • Hyperinsulinemia

 goto top of outline Abstract

Background/Aims: The metabolic syndrome (MeSy) may be related to Alzheimer’s disease (AD). Our aims were to investigate the association of the MeSy with incident dementia in a multiethnic elderly cohort in the United States. Methods: We conducted cross-sectional and prospective analyses in 2,476 men and women aged 65 years and older and with data available on the MeSy and dementia diagnosis in Northern New York City. MeSy was defined by the National Cholesterol Education Program Adult Treatment Program III and the European Group for the Study of Insulin Resistance criteria. Dementia was diagnosed using standard criteria. Results: No association was found between MeSy and prevalent dementia. After 4.4 years of follow-up, 236 individuals of the 1,833 without prevalent dementia developed dementia. MeSy was not associated with incident dementia. Of the components of the MeSy, diabetes and hyperinsulinemia were associated with an increased risk of incident AD [hazard ratio 1.4 (95% CI 1.0–2.1), and hazard ratio 1.4 (95% CI 0.9–2.7), respectively] and dementia associated with stroke [hazard ratio 1.9 (95% CI 1.1–3.1), and hazard ratio 2.3 (95% CI 1.1–4.7), respectively]. Conclusions: The MeSy was not associated with an increased dementia risk in a multiethnic elderly cohort, but diabetes and hyperinsulinemia were. In the elderly, examining diabetes and hyperinsulinemia separately may be preferable to using the MeSy as a risk factor.

Copyright © 2007 S. Karger AG, Basel


 goto top of outline References
  1. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–2752.
  2. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005;365:1415–1428.
  3. Abbott RD, Curb JD, Rodriguez BL, et al: Age-related changes in risk factor effects on the incidence of coronary heart disease. Ann Epidemiol 2002;12:173–181.
  4. Luchsinger JA: A work in progress: the metabolic syndrome. Sci Aging Knowledge Environ 2006;2006:pe19.

    External Resources

  5. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R: Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001;154:635–641.
  6. Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187–1192.
  7. Luchsinger JA, Reitz C, Honig LS, et al: Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005;65:545–551.
  8. Ott A, Stolk RP, van Harskamp F, et al: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937–1942.
  9. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L: Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004;63:1181–1186.
  10. Kivipelto M, Helkala EL, Laakso MP, et al: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population-based study. BMJ 2001;322:1447–1451.
  11. Launer LJ, Ross GW, Petrovitch H, et al: Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000;21:49–55.
  12. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K: Obesity in middle age and future risk of dementia: a 27-year longitudinal population-based study. BMJ 2005;330:1360.
  13. Ruitenberg A, Skoog I, Ott A, et al: Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001;12:33–39.
  14. Buchman AS, Wilson RS, Bienias JL, et al: Change in body mass index and risk of incident Alzheimer disease. Neurology 2005;65:892–897.
  15. Luchsinger JA, Patel B, Tang MX, Schupf N, Mayeux R: Measures of adiposity and dementia risk in the elderly. Arch Neurol 2007;64:392–398.
  16. Yaffe K, Kanaya A, Lindquist K, et al: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237–2242.
  17. Kwon HM, Kim BJ, Lee SH, et al: Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006;37:466–470.
  18. Kalmijn S, Foley D, White L, et al: Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000;20:2255–2260.
  19. Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187–1192.
  20. Reitz C, Tang MX, Luchsinger J, Mayeux R: Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705–714.
  21. Stern Y, Andrews H, Pittman J, et al: Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol 1992;49:453–460.
  22. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
  23. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545–548.
  24. 1990 Census of Population and Housing: Summary Tape File 1, Technical Documentation (Computer Program/Diskette). STF 1A Database, 1991.
  25. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
  26. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  27. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF: Modelling age-specific risk: application to dementia. Stat Med 1998;17:1973–1988.
  28. Vanhanen M, Koivisto K, Moilanen L, et al: Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006;67:843–847.
  29. Luchsinger JA, Mayeux R: Adiposity and Alzheimer’s disease. Curr Alzheimer Res 2007;4:127–134.
  30. Skoog I: Highs and lows of blood pressure: a cause of Alzheimer’s disease? Lancet Neurol 2003;2:334.
  31. Posner HB, Tang MX, Luchsinger J, et al: The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 2002;58:1175–1181.
  32. Stevens J, Cai J, Pamuk ER, et al: The effect of age on the association between body-mass index and mortality.N Engl J Med 1998;338:1–7.
  33. Weijenberg MP, Feskens EJ, Kromhout D: Age-related changes in total and high-density-lipoprotein cholesterol in elderly Dutch men. Am J Public Health 1996;86:798–803.
  34. Schupf N, Costa R, Luchsinger J, et al: Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005;53:219–226.
  35. McKeigue PM: Ethnic variation in insulin resistance and risk of type 2 diabetes; in Reaven GM, Laws A (eds): Insulin Resistance: The Metabolic Syndrome X. Totowa, Humana Press, 1999, pp 19–34.
  36. Luchsinger JA: Diabetes; in Aguirre-Molina M, Molina CW, Zambrana RE (eds): Health Issues in the Latino Community. San Francisco, Jossey-Bass, 2001, pp 277–300.
  37. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006;5:64–74.

 goto top of outline Author Contacts

José A. Luchsinger
Division of General Medicine
PH9East-105, 630 West 168th Street
New York, NY 10032 (USA)
Tel. +1 212 305 4730, Fax +1 212 305 9349, E-Mail jal94@columbia.edu


 goto top of outline Article Information

Accepted: March 15, 2007
Published online: July 18, 2007
Number of Print Pages : 8
Number of Figures : 1, Number of Tables : 4, Number of References : 37


 goto top of outline Publication Details

Dementia and Geriatric Cognitive Disorders

Vol. 24, No. 3, Year 2007 (Cover Date: August 2007)

Journal Editor: Chan-Palay, V. (New York, N.Y.)
ISSN: 1420–8008 (print), 1421–9824 (Online)

For additional information: http://www.karger.com/DEM


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.